Zobrazeno 1 - 10
of 199
pro vyhledávání: '"Ken Garber"'
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology. 40:1709-1713
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::36dd5b794ea75d5fd3012fc275199f88
https://doi.org/10.1038/s41587-022-01594-7
https://doi.org/10.1038/s41587-022-01594-7
Publikováno v:
Nature Biotechnology. 40:1551-1562
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::299e64888e2177b8b71a76e0c2e868ed
https://doi.org/10.1038/s41587-022-01530-9
https://doi.org/10.1038/s41587-022-01530-9
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::20aa39d73f3a0616b9aeeb2316cb56cd
https://doi.org/10.1038/s41587-023-01790-z
https://doi.org/10.1038/s41587-023-01790-z
Autor:
Ken Garber
Publikováno v:
Nature Reviews Drug Discovery. 21:699-701
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c0b9cf83d3a5dc6103965ea1b742a023
https://doi.org/10.1038/d41573-022-00156-5
https://doi.org/10.1038/d41573-022-00156-5
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology. 40:12-16
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::c688c98600d6ec26a7456a460a60e651
https://doi.org/10.1038/s41587-021-01173-2
https://doi.org/10.1038/s41587-021-01173-2
Publikováno v:
Nature Biotechnology. 39:1036-1047
Nature Biotechnology’s annual survey highlights university startups that are, among other things, rethinking how to deliver gene-editing therapy and tackling various metabolic conditions, immune disorders and cancer with microbiome treatments or im
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3768518166dcaac348bad42abfa940eb
https://doi.org/10.1038/s41587-021-01043-x
https://doi.org/10.1038/s41587-021-01043-x
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::8953b023459b81e633303f2bd2ca49be
https://doi.org/10.1038/d41587-022-00006-0
https://doi.org/10.1038/d41587-022-00006-0
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::565f86eb02267d9d63fbee1705785bf2
https://doi.org/10.1038/d41587-022-00005-1
https://doi.org/10.1038/d41587-022-00005-1
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology
Following mixed results in the clinic against COVID-19, antibody engineers are further optimizing SARS-CoV-2 antibodies with the aim of improving outcomes.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4ff14ad3092be56924541bc1ecfae66b
https://doi.org/10.1038/s41587-020-00791-6
https://doi.org/10.1038/s41587-020-00791-6
Autor:
Ken Garber
Publikováno v:
Nature Biotechnology. 38:909-912
Epizyme’s EZH2 inhibitor gains two approvals in quick succession — a milestone for this new class of epigenetic cancer drug that targets histone marks with greater precision than previous generations.
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::fb9a47f82c4982e60352c7bbb5c5ff02
https://doi.org/10.1038/s41587-020-0621-1
https://doi.org/10.1038/s41587-020-0621-1